ArticleInternational journal of nanomedicine2021
DPPG
Article in International journal of nanomedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 29 citations in OpenAlex.
- Heat-activated intravenous liposomal doxorubicin combined with mitomycin C hyperthermic intravesical chemotherapy (HIVEC) for treatment of bladder cancer.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2026Article
- Stimuli-Responsive Carriers for Delivery of Anticancer Bioactive Agents.Materials (Basel, Switzerland) · 2026Review
- Application and challenges of smart responsive multifunctional nanoplatforms in integrated diagnosis and treatment of bladder cancer and overcoming therapeutic resistance.Frontiers in oncology · 2026Review
- Hyperthermia-targeted rectal delivery of thermosensitive liposomal doxorubicin via intra-arterial and intravenous administration.Frontiers in pharmacology · 2026Article
- Progress on liposome delivery systems in the treatment of bladder cancer.RSC advances · 2025Review
- A Comprehensive Review of Current Approaches in Bladder Cancer Treatment.ACS pharmacology & translational science · 2025Review
- Innovative Delivery and Release Systems for Antioxidants and Other Active Substances in the Treatment of Cancer.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Recent Preclinical and Clinical Progress in Liposomal Doxorubicin.Pharmaceutics · 2023Review
- Review
- Liposomal Drug Delivery Systems for Cancer Therapy: The Rotterdam Experience.Pharmaceutics · 2022Review
- A scalable hyperthermic intravesical chemotherapy (HIVEC) setup for rat models of bladder cancer.Scientific reports · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCurrent treatment options for muscle-invasive bladder cancer (MIBC) are associated with substantial morbidity. Local release of doxorubicin (DOX) from phosphatidyldiglycerol-based thermosensitive liposomes (DPPG MATERIALS AND
methodsTwenty-one pigs were anaesthetized, and a urinary catheter equipped with a radiofrequency-emitting antenna for HT (60 minutes) was placed. Experimental groups consisted of iv low or full dose (20 or 60 mg/m
resultsIv DPPG
conclusionIv DPPG
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.